Angimmune
MD - RockvilleBiotechnology
Focus: Angimmune is a mid-cap biotechnology company headquartered in Rockville, MD, focused on anti-T cell immunotoxins for oncology applications. The company operates at 5,000+ employees, indicating a substantial research and development infrastructure.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Employees
5000+
Open Jobs
0
About Angimmune
AI assessmentNot HiringNo open roles listed right now. Follow Angimmune to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
A-dmDT390-bisFv(UCHT1)
T-cell LymphomasClinical Trials (3)
NCT00611208A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
Phase 2Help build intelligence for Angimmune
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.